Search Articles

View query in Help articles search

Search Results (1 to 10 of 61 Results)

Download search results: CSV END BibTex RIS


Population-Level Distribution, Risk Factors, and Burden of Mortality and Disability-Adjusted Life Years Attributable to Major Noncommunicable Diseases in Western Europe (1990-2021): Ecological Analysis

Population-Level Distribution, Risk Factors, and Burden of Mortality and Disability-Adjusted Life Years Attributable to Major Noncommunicable Diseases in Western Europe (1990-2021): Ecological Analysis

Neoplasms (cancers) accounted for approximately 27.1% (95% UI 28.6%-24.3%) of total deaths in Western Europe. The age-standardized death rate for neoplasms in the region was 125.8 per 100,000 population (95% UI 131.4-115.3) in the same year (Tables 1 and 2). The 3 cancer subtypes with the highest death burden in Western Europe in 2021 were lung cancer, colorectal cancer, and breast cancer (Table 2). The death burden of neoplasms in Western Europe has also shown a downward trend from 1990 to 2021.

Sumaira Mubarik, Shafaq Naeem, Hui Shen, Rabia Mubarak, Lisha Luo, Syeda Rija Hussain, Eelko Hak, Chuanhua Yu, Xiaoxue Liu

JMIR Public Health Surveill 2024;10:e57840

Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis

Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis

The increased popularity of GLP-1 RAs and the unsettled association of thyroid hyperplasias and neoplasms prompted further investigation into the most recent US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) data sets. In this study, we evaluated thyroid hyperplasia and neoplasm–related AEs that are reported as being associated with GLP-1 RA monotherapy when compared to sodium-glucose cotransporter-2 (SGLT-2) inhibitors monotherapy.

Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan

JMIRx Med 2024;5:e55976